Summary & Overview
HCPCS J9230: Mechlorethamine Hydrochloride 10 mg Injection
HCPCS Level II code J9230 denotes the injection of mechlorethamine hydrochloride (nitrogen mustard), 10 mg, used in chemotherapeutic treatment. This code captures the drug product itself rather than the infusion procedure and is relevant for oncology providers, infusion centers, and billing teams managing cancer therapy claims. Nationally, agents billed under HCPCS medicinal codes are tracked for utilization, payer coverage policies, and site-of-service billing practices.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides a concise overview of billing context for J9230, typical sites of service, and payer patterns. Readers will find practical benchmarks for how this HCPCS Level II drug code is categorized, a summary of common modifier usage when data is available, and clinical context for mechlorethamine administration.
The piece outlines what to expect for claim construction when billing the drug product separately from administration services, highlights payer coverage considerations at a national level, and summarizes the clinical indication implied by the drug description. Data not available in the input will be noted where relevant.
Billing Code Overview
HCPCS Level II code J9230 represents an injection of mechlorethamine hydrochloride (nitrogen mustard), 10 mg. This code is used to bill for administration of the chemotherapeutic agent in clinical settings.
Service type: Chemotherapy administration (intravenous or intralesional as clinically indicated)
Typical site of service: Outpatient infusion center, oncology clinic, or physician office
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a localized cutaneous or mucosal malignancy such as mycosis fungoides (cutaneous T-cell lymphoma) or localized skin cancers where topical or intralesional chemotherapy with mechlorethamine hydrochloride is indicated. The patient presents to an oncology infusion clinic, dermatology procedure suite, or hospital outpatient department for administration of J9230 — an injectable formulation of mechlorethamine 10 mg. The clinical workflow includes verification of diagnosis and indication, review of prior therapies, informed consent, baseline vital signs and laboratory tests as indicated, preparation of the drug by pharmacy under sterile technique, administration by a licensed clinician (dermatologist, medical oncologist, or trained advanced practice provider) via intralesional injection or as directed for topical compounding, observation for immediate adverse reactions, and documentation of dose, lot number, route, site, and any modifier to reflect circumstances of the service. Typical monitoring includes skin assessments, pain control, and scheduling of follow-up visits to assess treatment response and toxicity management.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Office/Outpatient Visit | Used when the injection is provided during a standard evaluation and management visit in the office setting. |